Brandon Gufford, PharmD, PhD
Adjunct Assistant Professor of Medicine
- Phone
- (317) 274-2847
- Address
-
R2 Room 402
CPHR
IN
Indianapolis, IN - PubMed:
-
Bio
Dr. Gufford's research interests include various aspects of drug disposition and action with a particular focus on drug-drug, and natural product-drug interactions. Brandon has more than a decade of experience evaluating drug disposition and interactions as a clinician, academic investigator, and clinical pharmacokineticist. Dr. Gufford has a wide range of drug metabolism and pharmacokinetics experience including in vitro assessments, clinical study design and optimization, pharmacogenetic considerations, and application of advanced modelling and simulation approaches. Brandon has experience with PK, PD, and PK/PD analyses of clinical data from Phase I-IV clinical trials with an emphasis on early phase drug development. Dr. Gufford has maintained an adjunct appointment with the Division of Clinical Pharmacology since 2018.
| Year | Degree | Institution |
|---|---|---|
| 2017 | Fellowship | Indiana University |
| 2015 | PhD | Washington State University |
| 2011 | PharmD | University of Nebraska at Omaha |
The goal of Dr. Gufford's translational research program is to improve the mechanistic understanding of interactions between conventional medications and natural products with a focus on patients infected with HIV. Our group is particularly interested in ways to better predict drug-drug and natural product-drug interactions that involve multiple components and active metabolites which alter drug disposition via multiple mechanisms. These complex interactions encompass simultaneous alteration of extrahepatic and hepatic metabolism and transport with the potential to cause adverse effects or be harnessed to yield therapeutic benefit. The complimentary tools used to understand these complex interactions include in vitro (bench research), in silico (computer modeling and simulation), and in vivo (clinical studies) approaches that span the gamut of the translational research spectrum.
Burgess KS; Ipe J; Swart M; Metzger IF; Lu J; Gufford BT; Thong N; Desta Z; Gaedigk R; Pearce RE; Gaedigk A; Liu Y; Skaar TC; Clinical pharmacology and therapeutics 2017 Sep 27
Gufford BT; Ainslie GR; White JR Jr; Layton ME; Padowski JM; Pollack GM; Paine MF; Clinical and translational science 2017 May 23
Pierson RC; Gufford BT; Desta Z; Eadon MT; Pharmacogenomics 2017 Jun 8
Eadon MT; Desta Z; Levy KD; Decker BS; Pierson RC; Pratt VM; Callaghan JT; Rosenman MB; Carpenter JS; Holmes AM; McDonald CA; Benson EA; Patil AS; Vuppalanchi R; Gufford BT; Dave N; Robarge JD; Hyder MA; Haas DM; Kreutz RP; Dexter PR; Skaar TC; Flockhart DA; Clinical pharmacology and therapeutics 2016 Mar 31
Masters AR; Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z; The Journal of pharmacology and experimental therapeutics 2016 Jun 2
Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z; Drug metabolism and disposition: the biological fate of chemicals 2016 Jan 22
Infectious Diseases
Complementary and Alternative Medicine
Drugs of Abuse
Management of Addiction